table of content
1 Introduction to Research & Analysis Reports
1.1 Oligonucleotide-based Therapies Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Oligonucleotide-based Therapies Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Oligonucleotide-based Therapies Overall Market Size
2.1 Global Oligonucleotide-based Therapies Market Size: 2022 VS 2030
2.2 Global Oligonucleotide-based Therapies Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Oligonucleotide-based Therapies Players in Global Market
3.2 Top Global Oligonucleotide-based Therapies Companies Ranked by Revenue
3.3 Global Oligonucleotide-based Therapies Revenue by Companies
3.4 Top 3 and Top 5 Oligonucleotide-based Therapies Companies in Global Market, by Revenue in 2022
3.5 Global Companies Oligonucleotide-based Therapies Product Type
3.6 Tier 1, Tier 2 and Tier 3 Oligonucleotide-based Therapies Players in Global Market
3.6.1 List of Global Tier 1 Oligonucleotide-based Therapies Companies
3.6.2 List of Global Tier 2 and Tier 3 Oligonucleotide-based Therapies Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Oligonucleotide-based Therapies Market Size Markets, 2022 & 2030
4.1.2 Antisense Oligonucleotide
4.1.3 Aptamer
4.1.4 Other
4.2 By Type - Global Oligonucleotide-based Therapies Revenue & Forecasts
4.2.1 By Type - Global Oligonucleotide-based Therapies Revenue, 2018-2023
4.2.2 By Type - Global Oligonucleotide-based Therapies Revenue, 2024-2030
4.2.3 By Type - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Oligonucleotide-based Therapies Market Size, 2022 & 2030
5.1.2 Neuromuscular Diseases
5.1.3 Hepatic VOD
5.1.4 Other
5.2 By Application - Global Oligonucleotide-based Therapies Revenue & Forecasts
5.2.1 By Application - Global Oligonucleotide-based Therapies Revenue, 2018-2023
5.2.2 By Application - Global Oligonucleotide-based Therapies Revenue, 2024-2030
5.2.3 By Application - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Oligonucleotide-based Therapies Market Size, 2022 & 2030
6.2 By Region - Global Oligonucleotide-based Therapies Revenue & Forecasts
6.2.1 By Region - Global Oligonucleotide-based Therapies Revenue, 2018-2023
6.2.2 By Region - Global Oligonucleotide-based Therapies Revenue, 2024-2030
6.2.3 By Region - Global Oligonucleotide-based Therapies Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Oligonucleotide-based Therapies Revenue, 2018-2030
6.3.2 US Oligonucleotide-based Therapies Market Size, 2018-2030
6.3.3 Canada Oligonucleotide-based Therapies Market Size, 2018-2030
6.3.4 Mexico Oligonucleotide-based Therapies Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Oligonucleotide-based Therapies Revenue, 2018-2030
6.4.2 Germany Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.3 France Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.4 U.K. Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.5 Italy Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.6 Russia Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.7 Nordic Countries Oligonucleotide-based Therapies Market Size, 2018-2030
6.4.8 Benelux Oligonucleotide-based Therapies Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Oligonucleotide-based Therapies Revenue, 2018-2030
6.5.2 China Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.3 Japan Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.4 South Korea Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.5 Southeast Asia Oligonucleotide-based Therapies Market Size, 2018-2030
6.5.6 India Oligonucleotide-based Therapies Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Oligonucleotide-based Therapies Revenue, 2018-2030
6.6.2 Brazil Oligonucleotide-based Therapies Market Size, 2018-2030
6.6.3 Argentina Oligonucleotide-based Therapies Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Oligonucleotide-based Therapies Revenue, 2018-2030
6.7.2 Turkey Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.3 Israel Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.4 Saudi Arabia Oligonucleotide-based Therapies Market Size, 2018-2030
6.7.5 UAE Oligonucleotide-based Therapies Market Size, 2018-2030
7 Oligonucleotide-based Therapies Companies Profiles
7.1 Biogen
7.1.1 Biogen Company Summary
7.1.2 Biogen Business Overview
7.1.3 Biogen Oligonucleotide-based Therapies Major Product Offerings
7.1.4 Biogen Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.1.5 Biogen Key News & Latest Developments
7.2 Sarepta Therapeutics
7.2.1 Sarepta Therapeutics Company Summary
7.2.2 Sarepta Therapeutics Business Overview
7.2.3 Sarepta Therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.2.4 Sarepta Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.2.5 Sarepta Therapeutics Key News & Latest Developments
7.3 Jazz Pharmaceuticals
7.3.1 Jazz Pharmaceuticals Company Summary
7.3.2 Jazz Pharmaceuticals Business Overview
7.3.3 Jazz Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
7.3.4 Jazz Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.3.5 Jazz Pharmaceuticals Key News & Latest Developments
7.4 Bausch & Lomb
7.4.1 Bausch & Lomb Company Summary
7.4.2 Bausch & Lomb Business Overview
7.4.3 Bausch & Lomb Oligonucleotide-based Therapies Major Product Offerings
7.4.4 Bausch & Lomb Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.4.5 Bausch & Lomb Key News & Latest Developments
7.5 Alnylam Pharmaceuticals
7.5.1 Alnylam Pharmaceuticals Company Summary
7.5.2 Alnylam Pharmaceuticals Business Overview
7.5.3 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Major Product Offerings
7.5.4 Alnylam Pharmaceuticals Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.5.5 Alnylam Pharmaceuticals Key News & Latest Developments
7.6 Dynavax Technologies
7.6.1 Dynavax Technologies Company Summary
7.6.2 Dynavax Technologies Business Overview
7.6.3 Dynavax Technologies Oligonucleotide-based Therapies Major Product Offerings
7.6.4 Dynavax Technologies Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.6.5 Dynavax Technologies Key News & Latest Developments
7.7 Kastle therapeutics
7.7.1 Kastle therapeutics Company Summary
7.7.2 Kastle therapeutics Business Overview
7.7.3 Kastle therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.7.4 Kastle therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.7.5 Kastle therapeutics Key News & Latest Developments
7.8 Akcea Therapeutics
7.8.1 Akcea Therapeutics Company Summary
7.8.2 Akcea Therapeutics Business Overview
7.8.3 Akcea Therapeutics Oligonucleotide-based Therapies Major Product Offerings
7.8.4 Akcea Therapeutics Oligonucleotide-based Therapies Revenue in Global Market (2018-2023)
7.8.5 Akcea Therapeutics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
